[Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

• Authors:
  • Jun Fujiwara
  • Yoshihiro Sowa
  • Mano Horinaka
  • Makoto Koyama
  • Miki Wakada
  • Tsuneharu Miki
  • Toshiyuki Sakai

• View Affiliations

  
  Affiliations: Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan, Department of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
• Published online on: November 25, 2015     https://doi.org/10.3892/ijo.2015.3265
• Pages: 854-854

• Copyright: © Fujiwara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Article

View Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6